Jump Financial LLC Acquires 89,053 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Jump Financial LLC boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 326.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,341 shares of the biopharmaceutical company's stock after acquiring an additional 89,053 shares during the quarter. Jump Financial LLC owned approximately 0.07% of ACADIA Pharmaceuticals worth $3,643,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. RTW Investments LP raised its stake in shares of ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock valued at $241,255,000 after acquiring an additional 1,793,288 shares in the last quarter. Fred Alger Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 38.7% in the third quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company's stock worth $64,789,000 after buying an additional 867,818 shares during the last quarter. Sectoral Asset Management Inc. bought a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth $4,376,000. Qube Research & Technologies Ltd grew its stake in ACADIA Pharmaceuticals by 757.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company's stock valued at $4,437,000 after buying an additional 188,080 shares during the last quarter. Finally, Fisher Asset Management LLC bought a new position in ACADIA Pharmaceuticals in the 4th quarter worth $4,479,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ACAD shares. HC Wainwright decreased their target price on ACADIA Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday. Citigroup lowered their price objective on ACADIA Pharmaceuticals from $30.19 to $30.00 and set a "buy" rating on the stock in a research report on Thursday. Mizuho reduced their target price on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Thursday. Royal Bank of Canada lowered their price target on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, February 28th. Finally, Bank of America dropped their price objective on shares of ACADIA Pharmaceuticals from $26.00 to $22.00 and set a "neutral" rating for the company in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $28.94.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 5,577 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.67, for a total transaction of $137,584.59. Following the sale, the chief executive officer now directly owns 101,890 shares in the company, valued at approximately $2,513,626.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 5,577 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $24.67, for a total transaction of $137,584.59. Following the completion of the transaction, the chief executive officer now owns 101,890 shares in the company, valued at approximately $2,513,626.30. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Mark C. Schneyer sold 3,503 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $59,340.82. Following the completion of the sale, the chief financial officer now directly owns 32,053 shares in the company, valued at approximately $542,977.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,116 shares of company stock valued at $1,625,639. Company insiders own 27.50% of the company's stock.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock traded up $0.04 during trading hours on Friday, reaching $15.25. 2,310,110 shares of the company's stock traded hands, compared to its average volume of 1,704,760. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $15.11 and a fifty-two week high of $33.99. The firm's 50 day moving average is $18.32 and its 200-day moving average is $23.11. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -1,523.48 and a beta of 0.42.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The firm had revenue of $205.83 million for the quarter, compared to analyst estimates of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.43% and a negative net margin of 0.21%. The company's quarterly revenue was up 73.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. Analysts predict that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.